Ad
related to: central serous retinopathy cure video- Study Results
See Clinical Study
Results and Other HCP Info
- Dosing & Administration
View Dosing Information
& Administration Options.
- Financial Support Info
HCPs - Receive Info About Financial
Support Options For Patients.
- Dosing Information
Find PAVBLU™ Dosing And
Administration Info.
- Amgen® SupportPlus
See Amgen® SupportPlus & How It May
Help Patients.
- About Biosimilars
Review Important Info. View
Full Prescribing & Safety Info
- Study Results
Search results
Results From The WOW.Com Content Network
Central serous chorioretinopathy (CSC or CSCR), also known as central serous retinopathy (CSR), is an eye disease that causes visual impairment, often temporary, usually in one eye. [ 1 ] [ 2 ] When the disorder is active it is characterized by leakage of fluid under the retina that has a propensity to accumulate under the central macula.
Treatment consists of three phases of immunotherapy: 1. Acute phase: IV steroids (methylprednisolone 1 mg/kg) for 3–5 days or plasmapheresis are given to restore visual function. [3] 2. Intermediate phase: Oral steroids (typically prednisone 1 mg/kg) with taper are given to stabilize vision. [3] 3.
Central serous chorioretinopathy (pachychoroid stage II) with subretinal fluid (black triangle in the middle) and a markedly thickened, congested choroid (white arrowheads). Pachychoroid disorders of the macula represent a group of diseases affecting the central part of the retina of the eye , the macula .
Chorioretinitis is an inflammation of the choroid (thin pigmented vascular coat of the eye) and retina of the eye. It is a form of posterior uveitis.Inflammation of these layers can lead to vision-threatening complications.
Central or paracentral scotoma [2] [3] Vision loss due to solar retinopathy is typically reversible, [4] lasting for as short as one month [2] to over one year. [3] The fundus changes are variable and usually bilateral, mild cases often show no alteration and moderate to severe cases show a foveal yellow spot on the first days after exposure ...
It occurs most often around 1.5 years after treatment and results in irreversible and severe vision loss, which may also be associated with damage to the retina (radiation retinopathy). This is thought to be due to damage to dividing glial and vascular endothelial cells.
Treatment of toxic and nutritional optic neuropathy is dictated by the cause of the disorder. Toxic optic neuropathy is treated by identification and removal of the offending agent. Depending upon the individual affected, the nature of the agent, total exposure prior to removal, and degree of vision loss at the time of diagnosis, the prognosis ...
Verteporfin (trade name Visudyne), a benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration.